Loading
Cancer cells can survive a drug because surrounding normal cells feed them growth signals. Blocking those signals could make existing drugs work better and longer.
Fibroblast- and macrophage-derived factors including HGF, FGFs and neuregulin rescue tumour cells from targeted therapy in co-culture and in vivo, an effect largely invisible in monoculture screens. Environment-mediated resistance argues for combining targeted agents with blockade of the specific rescuing ligand or its receptor, selected by profiling the tumour's own stroma rather than the tumour cells alone.
Shares Patritumab deruxtecan, HER3.
Shares Patritumab deruxtecan, HER3.
Shares Patritumab deruxtecan, HER3.
Shares FAP, Single-cell & spatial profiling, Cold tumours and the immunosuppressive microenvironment.
Shares FAP, Single-cell & spatial profiling.
Shares Single-cell & spatial profiling, Acquired resistance to every therapy.
Shares HER3, Single-cell & spatial profiling, Acquired resistance to every therapy.
Shares Single-cell & spatial profiling, Cold tumours and the immunosuppressive microenvironment.